Get notified when SLXN files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (new) — Auditor opinion includes going concern explanatory paragraph; management disclosed substantial doubt about ability to continue as going concern due to cash runway of only several months as of March 31, 2026.
  • Nasdaq Equity Deficiency (new) — Shareholders' equity fell below Nasdaq's $2.5M minimum requirement after being compliant at $2.6M as of March 31, 2026; company is dependent on this offering to regain compliance, with no assurance of success.
  • Mandatory Monitoring Period (new) — Company is under Nasdaq panel monitoring through September 23, 2026; any new equity deficiency during this period triggers immediate delisting proceedings without the usual cure period.
  • Reverse Split Delisting Trigger (new) — If share price closes below $1.00 for 30 consecutive days before May 29, 2027 (one year after May 2026 reverse split), company faces immediate delisting proceedings.
NASDAQ: SLXN Silexion Therapeutics Corp S-1/A

Silexion prices $5M offering at $1.87/share, nearly tripling share count amid Nasdaq equity gap

Filed August 10, 2026 · Compared to S-1 Aug 7, 2026 · ~2 min read

Key Changes

  • high

    Offering of up to 2.67M shares at $1.87 would increase outstanding shares 198% (from 1.35M to 4.02M), with net proceeds of $4.3M extending cash runway into Q1 2027 at best; without the raise, existing cash covers only several months.

    Use of Proceeds / Dilution view on EDGAR →
  • high

    Shareholders' equity currently below Nasdaq's $2.5M minimum; company is under mandatory monitoring through Sept 2026 with no cure period for repeat deficiencies, and faces immediate delisting if share price closes below $1.00 for 30 days before May 2027.

    Risk Factors: Nasdaq Compliance verify on EDGAR →
  • high

    Auditor opinion includes going concern explanatory paragraph; management concluded substantial doubt exists about ability to continue as going concern due to cash runway of only several months as of March 31, 2026.

    MD&A / Experts view on EDGAR →

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.

Partner

Trade SLXN commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 16, 2026 · How we verify